MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
warrants
$3,949,732
Proceeds from sale of
common stock
$395,474
Proceeds from related
party loans
$62,347
Cash received in
acquisition of phytanix bio
-$943,180
Net cash provided by
financing activities
$4,407,553
Net cash provided by
investing activities
$943,180
Net increase in cash
$2,788,067
Canceled cashflow
$2,562,666
Change in fair value of
derivative liabilities
-$1,930,245
Increase in note payable
for acquisition of...
$583,880
Derivative expense
-$343,399
Amortization of debt discount
to interest...
$243,353
Stock based
compensation
$230,995
Accrued liabilities
$158,912
Vat receivable
-$29,481
Depreciation expense
$25,143
Net cash used in
operating activities
-$2,562,666
Canceled cashflow
$3,545,408
Net loss
-$5,927,019
Accounts payable
-$177,180
Prepaid expenses
$3,838
Inventories
$37
Back
Back
Cash Flow
source: myfinsight.com
Protagenic Therapeutics, Inc. new (PTIXW)
Protagenic Therapeutics, Inc. new (PTIXW)